Recent Updates
Recently added Catalysts
MDXG Negative Sentiment Score: 25/100

MiMedx Group Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Key Takeaway: MiMedx Group, Inc. is being investigated by Block & Leviton for possible violations of securities laws after the company disclosed a warning letter from the FDA concerning its Axiofill product. The FDA indicated that Axiofill is improperly classified under regulations, which has led to concerns over its marketability and compliance. Following this news, MiMedx's stock experienced a significant drop of more than 10%. Investors who have incurred losses are encouraged to contact Block & Leviton for potential recovery actions.

Market Sentiment Analysis

CONCERNS & RISKS

  • MiMedx Group is under investigation for potential securities law violations, indicating serious legal issues.
  • The company received a warning from the FDA regarding its Axiofill product, suggesting compliance problems.
  • Following the disclosure of the FDA warning, shares of MiMedx dropped over 10%, reflecting a loss of investor confidence.

Full Press Release Details

BOSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating MiMedx Group, Inc. (NASDAQ: MDXG) for potential securities law violations. Investors who have lost money in their MiMedx Group, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/mdxg.
What is this all about?
After the market closed on December 29, 2023, MiMedx disclosed receipt of a warning letter from the U.S. Food and Drug Administration (“FDA”) regarding production of its placental-derived tissue product, Axiofill. The Company said the FDA’s position is that Axiofill does not meet the requirements as a Section 361 product and is therefore subject to enforcement as a Section 351 product.
Shares of MiMedx Group, Inc. stock dropped more than 10% in intraday trading on January 2, 2024.
Anyone who purchased MiMedx Group, Inc. securities and has lost money may be eligible, whether or not they have sold their investment. Investors should contact Block & Leviton to learn more.
What is Block & Leviton doing?
Block & Leviton is investigating whether the Company committed securities law violations and may file an action to attempt to recover losses on behalf of investors who have lost money.
What should you do next?
If you've lost money on your investment, you should contact Block & Leviton to learn more via our case website, by email at cases@blockleviton.com, or by phone at (617) 398-5600.
Why should you contact Block & Leviton?
Block & Leviton is widely regarded as one of the leading securities class action firms in the country. Our attorneys have recovered billions of dollars for defrauded investors and are dedicated to obtaining significant recoveries on behalf of our clients through active litigation in the federal courts across the country. Many of the nation's top institutional investors hire us to represent their interests. You can learn more about us at our website, www.blockleviton.com, or call (617) 398-5600 or email cases@blockleviton.com with any questions.
This notice may constitute attorney advertising.
260 Franklin St., Suite 1860
Phone: (617) 398-5600
SOURCE: Block & Leviton LLP

Tags

Frequently Asked Questions

What is the focus of Block & Leviton's investigation?

Block & Leviton is investigating MiMedx Group for possible securities law violations.

What caused MiMedx Group's stock to drop?

The stock fell over 10% after MiMedx received an FDA warning letter regarding Axiofill.

Who should contact Block & Leviton?

Investors who lost money in MiMedx Group, regardless of whether they sold their shares.

Why choose Block & Leviton for legal support?

Block & Leviton is a top securities class action firm known for recovering billions for clients.

How can I reach Block & Leviton?

Contact them via their website, email at cases@blockleviton.com, or call (617) 398-5600.

Last updated: Jan 17, 2024